These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3603312)

  • 1. Population pharmacokinetics of phenytoin in South African black patients.
    Miller R; Rheeders M; Klein C; Suchet I
    S Afr Med J; 1987 Aug; 72(3):188-90. PubMed ID: 3603312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
    Koren G; Brand N; MacLeod SM
    Ther Drug Monit; 1984; 6(1):11-4. PubMed ID: 6710554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa.
    Valodia P; Seymour MA; Miller R; McFadyen ML; Folb PI
    Ther Drug Monit; 1999 Feb; 21(1):57-62. PubMed ID: 10051055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of phenytoin therapy in adults with epilepsy in the Western Cape, South Africa.
    Valodia PN; Seymour MA; Kies BM; Folb PI
    J Clin Pharm Ther; 1999 Oct; 24(5):381-5. PubMed ID: 10583702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state pharmacokinetics of phenytoin from routinely collected patient data.
    Grasela TH; Sheiner LB; Rambeck B; Boenigk HE; Dunlop A; Mullen PW; Wadsworth J; Richens A; Ishizaki T; Chiba K
    Clin Pharmacokinet; 1983; 8(4):355-64. PubMed ID: 6617043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics].
    Rui JZ; Cai MH; Chu XM; Chen G
    Yao Xue Xue Bao; 1995; 30(3):172-8. PubMed ID: 7639079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of phenytoin from routine clinical data in Japan.
    Yukawa E; Higuchi S; Aoyama T
    J Clin Pharm Ther; 1989 Feb; 14(1):71-7. PubMed ID: 2921305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model.
    Odani A; Hashimoto Y; Takayanagi K; Otsuki Y; Koue T; Takano M; Yasuhara M; Hattori H; Furusho K; Inui K
    Biol Pharm Bull; 1996 Mar; 19(3):444-8. PubMed ID: 8924916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of phenytoin in routine clinic patients in Malaysia.
    Ismail R; Rahman AF; Chand P
    J Clin Pharm Ther; 1994 Aug; 19(4):245-8. PubMed ID: 7989403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical response in epilepsy in relation to total and free serum levels of phenytoin.
    Peterson GM; Khoo BH; von Witt RJ
    Ther Drug Monit; 1991 Sep; 13(5):415-9. PubMed ID: 1957333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three Michaelis-Menten pharmacokinetic dosing methods compared with physician dosing of phenytoin in an outpatient neurology practice.
    Spruill WJ; Wade WE; Cobb HH; Akbari S
    Pharmacotherapy; 2001 Nov; 21(11):1407-14. PubMed ID: 11714214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
    Bourgeois BF; Wad N
    Ther Drug Monit; 1985; 7(4):405-10. PubMed ID: 4082240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of source of population data on phenytoin dosage predictions in black patients.
    Miller R; Rheeders M
    Clin Pharm; 1989 Jan; 8(1):56-9. PubMed ID: 2912667
    [No Abstract]   [Full Text] [Related]  

  • 14. Individualization of phenytoin dosage regimens.
    Ludden TM; Allen JP; Valutsky WA; Vicuna AV; Nappi JM; Hoffman SF; Wallace JE; Lalka D; McNay JL
    Clin Pharmacol Ther; 1977 Mar; 21(3):287-93. PubMed ID: 837647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and slow release phenytoin in epileptic patients at steady state: assessment of relative bioavailability utilizing Michaelis-Menten parameters.
    Sawchuk RJ; Pepin SM; Leppik IE; Gumnit RJ
    J Pharmacokinet Biopharm; 1982 Aug; 10(4):383-91. PubMed ID: 7153871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interindividual variation in the extent and rate of phenytoin accumulation.
    Levine M; Orr J; Chang T
    Ther Drug Monit; 1987 Jun; 9(2):171-6. PubMed ID: 3617156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.
    Hoppel C; Garle M; Rane A; Sjöqvist F
    Clin Pharmacol Ther; 1977 Mar; 21(3):294-300. PubMed ID: 837648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salivary phenytoin concentrations in epilepsy and in chronic renal failure.
    Reynolds F; Ziroyanis PN; Jones NF; Smith SE
    Lancet; 1976 Aug; 2(7982):384-6. PubMed ID: 73850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
    Deleu D; Aarons L; Ahmed IA
    Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a nomogram for estimating the rate of phenytoin accumulation.
    Levine M; Orr J; Chang T
    Ther Drug Monit; 1987 Jun; 9(2):166-70. PubMed ID: 3617155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.